Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P56645: Variant p.Met1028Thr

Period circadian protein homolog 3
Gene: PER3
Feedback?
Variant information Variant position: help 1028 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LB/B The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Methionine (M) to Threonine (T) at position 1028 (M1028T, p.Met1028Thr). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and hydrophobic (M) to medium size and polar (T) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Polymorphism: help The number of repeats of 18 amino acids in positions 966 to 1055 is polymorphic and varies among at least 2 different alleles. Alleles corresponding in size to a 4 (PER3.4) and 5 (PER3.5) repeats have been described. The sequence shown is that of allele PER3.5. In most populations around 10% of individuals are homozygous for the 5-repeat (PER3.5), whereas approximately 50% are homozygous for the 4-repeat (PER3.4). In some populations in Papua New Guinea the prevalence of the various genotypes appears to be reversed. These repeats and polymorphism are not present in non-primate mammals. Homozygosity for PER3.5 is more likely to show morning preference, whereas homozygosity for the PER3.4 associates with evening preferences. PER3.5 homozygous show vulnerability to sleep loss with a greater cognitive decline in response to total sleep deprivation (PubMed:11306557, PubMed:17346965, PubMed:19716732, PubMed:24439663, PubMed:24577121). Additional information on the polymorphism described.
Variant description: help Only found in PER3.4 allele. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 1028 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 1201 The length of the canonical sequence.
Location on the sequence: help LSTGSPPMKNPSHPTASTLS M GLPPSRTPSHPTATVLSTGS The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 1201 Period circadian protein homolog 3
Repeat 1019 – 1036 4
Region 952 – 1067 Disordered
Region 965 – 1054 5 X 18 AA tandem repeats of S-[HP]-[AP]-T-[AT]-[GST]-[ATV]-L-S-[MT]-G-[LS]-P-P-[MRS]-[EKR]-[NST]-P



Literature citations
Association of structural polymorphisms in the human period3 gene with delayed sleep phase syndrome.
Ebisawa T.; Uchiyama M.; Kajimura N.; Mishima K.; Kamei Y.; Katoh M.; Watanabe T.; Sekimoto M.; Shibui K.; Kim K.; Kudo Y.; Ozeki Y.; Sugishita M.; Toyoshima R.; Inoue Y.; Yamada N.; Nagase T.; Ozaki N.; Ohara O.; Ishida N.; Okawa M.; Takahashi K.; Yamauchi T.;
EMBO Rep. 2:342-346(2001)
Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2); NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 44-91 AND 724-882 (ISOFORMS 1/2); VARIANTS GLY-639; PRO-827; ALA-856; 1001-SER--PRO-1018 DEL; THR-1028 AND ARG-1149;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.